Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 7/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 7/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156345 | 0.89 | PLK1 (0.42) | GPR119MEN1PLK1CNR2 | |
| SCHEMBL31579034 | 0.83 | CNR2 (0.44) | GPR119MEN1PLK1CNR2 | |
| SCHEMBL19369086 | 0.83 | MEN1 (0.33) | GPR119MEN1 | |
| SCHEMBL19358789 | 0.80 | DTYMK (0.43) | GPR119CNR2 | |
| SCHEMBL29480889 | 0.80 | DTYMK (0.43) | GPR119CNR2 | |
| SCHEMBL29480900 | 0.78 | CNR2 (0.36) | GPR119RETCNR2 | |
| SCHEMBL20847265 | 0.78 | CNR2 (0.36) | GPR119RETCNR2 | |
| SCHEMBL19358796 | 0.78 | CNR2 (0.36) | GPR119RETCNR2 | |
| SCHEMBL17596556 | 0.77 | GPR119 (0.40) | GPR119CNR2 | |
| SCHEMBL20259684 | 0.75 | PIM1 (0.32) | MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018106818-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106818-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| WO-2016040330-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | MLLT1, MEN1, TERF2IP | GPR119 4361/4885RET 239/4885EGLN2 1635/4885 |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MEN1, TERF2IP | GPR119 4361/4885RET 239/4885EGLN2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.